<p>Dicerna is applying its proprietary RNAi technology to discover and develop innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. This second-generation gene-silencing technology can knock down the expression of a targeted gene in a way that is highly selective, specific and more potent than other RNAi approaches. The company's lead programme is currently in Phase I trials as a potential cancer treatment. Dicerna went public in January 2014.</p>